OncoMatch/Clinical Trials/NCT05333328
OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk
Is NCT05333328 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Ovarian function suppression with endocrine treatments for breast cancer.
Treatment: Ovarian function suppression with endocrine treatments — Among ER+HER2- premenopausal patients with N1 who undergoes primary breast surgery, we will identify the patients with a genomic low risk using the multigene-assay (OncoFREE®). In these, ovarian function suppression with endocrine therapies including either tamoxifen or aromatase-inhibitors will be administered for 5 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 overexpression (ER+)
ER+
Required: HER2 (ERBB2) wild-type (HER2-)
HER2-
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05333328 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require ESR1?
Yes, ESR1 overexpression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 50 years or younger and at least 20 years old.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages